Filtered By:
Condition: Ischemic Stroke
Drug: Gilenya

This page shows you your search results in order of date.

Order by Relevance | Date

Total 18 results found since Jan 2013.

The impact of fingolimod on Treg function in brain ischaemia
In conclusion, fingolimod seems to improve the suppressive function of Treg post-stroke while also increasing the resistance of CD4+ effector cells to this suppression. Fingolimod's capacity to increase both effector and regulatory functions may explain the lack of consistent improvement in functional recovery in experimental brain ischaemia.PMID:37366289 | DOI:10.1002/eji.202350370
Source: European Journal of Immunology - June 27, 2023 Category: Allergy & Immunology Authors: Kyle Malone Jennifer A Shearer Christian Waeber Anne C Moore Source Type: research

The efficacy and safety of fingolimod plus standardized treatment versus standardized treatment alone for acute ischemic stroke: A systematic review and meta ‐analysis
This study was conducted according to the PRISMA (Preferred Reporting Items for Systemic review and Meta-Analysis) statement. We searched for publications on the PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical trials, CNKI, Wanfang Data, VIP, CBM up to August 2021. We compiled five studies; a main meta-analysis forest plots were conducted for the values of the proportion of patients whose modified Rankin scale (MRS) score was 0 –1 at day 90. There were heterogeneities in each study; the method of sensitivity analysis was performed. A sensitivity analysis was performed with a mean difference (MD) ...
Source: Pharmacology Research and Perspectives - May 19, 2022 Category: Drugs & Pharmacology Authors: Peng Bai, Runxiu Zhu, Ping Wang, Feng Jiang, Jin Zhen, Yuan Yao, Chenhui Zhao, Zihong Liang, Meiling Wang, Bin Liu, Min Li, Na Li, Jun Yuan Tags: ORIGINAL ARTICLE Source Type: research

The emerging role of FTY720 as a sphingosine 1 ‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms
Three important mechanisms for neuroprotective effects of FTY720 have been described. Functional antagonistic, functional agonistic and receptor-independent mechanisms. Here, we review these mechanisms in more details and describe animal model and in clinical trial studies AbstractFinding novel and effective drugs for the treatment of ischemic stroke is warranted because there is not a definitive treatment for this prevalent disease. Due to the relevance between the sphingosine 1-phosphate (S1P) receptor and several neurological diseases including ischemic stroke, it seems that fingolimod (FTY720), as an agonist of S1P rec...
Source: Brain and Behavior - May 10, 2021 Category: Neurology Authors: Maryam Naseh, Jafar Vatanparast, Ali Rafati, Mahnaz Bayat, Masoud Haghani Tags: REVIEW Source Type: research

Acute Treatment With Fingolimod Does Not Confer Long-Term Benefit in a Mouse Model of Intracerebral Haemorrhage
Intracerebral haemorrhage (ICH) has no specific treatment, but accounts for up to 15% of all strokes and has the highest mortality. Fingolimod (FTY720) is an immunomodulator approved for the management of multiple sclerosis, with abundant evidence of efficacy in experimental ischemic stroke, and more limited evidence in experimental ICH. The goal of this study was to confirm the efficacy of fingolimod in experimental ICH using rigorous and statistically well-powered studies. ICH was induced in C57BL/6JOlaHsd male and female mice by intrastriatal bacterial collagenase injection. Fingolimod (0.5 mg/kg) or saline was adminis...
Source: Frontiers in Pharmacology - January 8, 2021 Category: Drugs & Pharmacology Source Type: research

Neuroinflammation in hemorrhagic transformation after tissue plasminogen activator thrombolysis: Potential mechanisms, targets, therapeutic drugs and biomarkers.
Abstract Hemorrhagic transformation (HT) is a common and serious complication following ischemic stroke, especially after tissue plasminogen activator (t-PA) thrombolysis, which is associated with increased mortality and disability. Due to the unknown mechanisms and targets of HT, there are no effective therapeutic drugs to decrease the incidence of HT. In recent years, many studies have found that neuroinflammation is closely related to the occurrence and development of HT after t-PA thrombolysis, including glial cell activation in the brain, peripheral inflammatory cell infiltration and the release of inflammato...
Source: International Immunopharmacology - December 6, 2020 Category: Allergy & Immunology Authors: Ma G, Pan Z, Kong L, Du G Tags: Int Immunopharmacol Source Type: research

Fingolimod promotes angiogenesis and attenuates ischemic brain damage via modulating microglial polarization.
CONCLUSIONS: Our research indicated that FTY720 treatment promoted angiogenesis via microglial M2 polarization and exerted neuroprotection in PT ischemic stroke. PMID: 31626784 [PubMed - as supplied by publisher]
Source: Brain Research - October 14, 2019 Category: Neurology Authors: Shang K, He J, Zou J, Qin C, Lin L, Zhou LQ, Yang LL, Wu LJ, Wang W, Zhan KB, Tian DS Tags: Brain Res Source Type: research

Repurposing multiple sclerosis drugs: a review of studies in other neurological and psychiatric conditions.
Abstract Treatment options for multiple sclerosis (MS) have improved in the past 20 years, with new oral disease-modifying drugs and monoclonal antibodies becoming available. The success seen with these drugs in MS, and their various mechanisms of action, has led to them being investigated in other neurological and psychiatric disorders. This review article summarises the ongoing and completed studies of MS drugs in neurological and psychiatric conditions other than MS. The most promising results are for interferon beta in human T cell leukaemia virus 1 associated myelopathy/tropical spastic paraparesis and glioma...
Source: Drug Discovery Today - May 13, 2019 Category: Drugs & Pharmacology Authors: Rommer PS, Sellner J Tags: Drug Discov Today Source Type: research

Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow
ObjectiveThe present study was undertaken to determine the efficacy of coadministration of fingolimod with alteplase in acute ischemic stroke patients in a delayed time window.MethodsThis was a prospective, randomized, open ‐label, blinded endpoint clinical trial, enrolling patients with internal carotid artery or middle cerebral artery proximal occlusion within 4.5 to 6 hours from symptom onset. Patients were randomly assigned to receive alteplase alone or alteplase with fingolimod. All patients underwent pretreatme nt and 24‐hour noncontrast computed tomography (CT)/perfusion CT/CT angiography. The coprimary endpoint...
Source: Annals of Neurology - November 2, 2018 Category: Neurology Authors: De ‐Cai Tian, Kaibin Shi, Zilong Zhu, Jia Yao, Xiaoxia Yang, Lei Su, Sheng Zhang, Meixia Zhang, Rayna J. Gonzales, Qiang Liu, DeRen Huang, Michael F. Waters, Kevin N. Sheth, Andrew F. Ducruet, Ying Fu, Min Lou, Fu‐Dong Shi Tags: Research Article Source Type: research

Fingolimod Enhances the Efficacy of Delayed Alteplase Administration in Acute Ischemic Stroke by Promoting Anterograde Reperfusion and Retrograde Collateral Flow
Annals of Neurology,Volume 0, Issue ja, -Not available-.
Source: Annals of Neurology - October 8, 2018 Category: Neurology Authors: De ‐Cai Tian, Kaibin Shi, Zilong Zhu, Jia Yao, Xiaoxia Yang, Lei Su, Sheng Zhang, Meixia Zhang, Rayna J. Gonzales, Qiang Liu, DeRen Huang, Michael F. Waters, Kevin N. Sheth, Andrew F. Ducruet, Ying Fu, Min Lou, Fu‐Dong Shi Source Type: research

Fingolimod Protects Against Ischemic White Matter Damage by Modulating Microglia Toward M2 Polarization via STAT3 Pathway Basic Sciences
Conclusions—Our study suggested that FTY720 might be a potential therapeutic drug targeting brain inflammation by skewing microglia toward M2 polarization after chronic cerebral hypoperfusion.
Source: Stroke - November 27, 2017 Category: Neurology Authors: Chuan Qin, Wen-Hui Fan, Qian Liu, Ke Shang, Madhuvika Murugan, Long-Jun Wu, Wei Wang, Dai-Shi Tian Tags: Ischemic Stroke, Vascular Disease Original Contributions Source Type: research

Fingolimod (FTY720) reduces cortical infarction and neurological deficits during ischemic stroke through potential maintenance of microvascular patency.
Abstract Fingolimod (FTY720) a functional sphingosine-1-phosphate receptor 1 (S1P1) antagonist reduces infarct volume and improves neurological deficits in different rodent stroke models by modulating inflammatory and immune processes. However, studies on FTY720 regarding its non-immunological efficacy on ischemic cerebral tissue are sparse. Here we investigated whether FTY720 has cytoprotective and restorative properties following ischemic stroke in mice. Male C57Bl/6 mice received FTY720 (1mg/kg) or a vehicle solution intraperitoneally immediately prior to transient middle cerebral artery occlusion (tMCAO; 30 mi...
Source: Current Neurovascular Research - August 22, 2016 Category: Neurology Authors: Fluri F, Schuhmann MK, Krstić M, Kleinschnitz C Tags: Curr Neurovasc Res Source Type: research

Clinical Trials of Immunomodulation in Ischemic Stroke
Abstract Inflammatory mechanisms are currently considered as a prime target for stroke therapy. There is evidence from animal studies that immune signals and mediators can have both detrimental and beneficial effects in particular stages of the disease process. Moreover, several of these mechanisms are turned on with sufficient delay after ischemia onset to make them amenable to therapeutic intervention. Several clinical proof-of concept trials have investigated the efficacy of different immunomodulatory approaches in patients with stroke. Trials targeting the innate immune system have focused on reduction of micr...
Source: Neurotherapeutics - July 12, 2016 Category: Neurology Source Type: research

Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation
Publication date: Available online 11 May 2016 Source:The Lancet Neurology Author(s): Ángel Chamorro, Ulrich Dirnagl, Xabier Urra, Anna M Planas Treatments for acute ischaemic stroke continue to evolve after the superior value of endovascular thrombectomy was confirmed over systemic thrombolysis. Unfortunately, numerous neuroprotective drugs have failed to show benefit in the treatment of acute ischaemic stroke, making the search for new treatments imperative. Increased awareness of the relevance of rigorous preclinical testing, and appropriate selection of study participants, might overcome the barriers to progress...
Source: The Lancet Neurology - May 11, 2016 Category: Neurology Source Type: research